Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 9:09 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 847 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Hyperlipidaemia Clear all

Conditions: Obesity, Overweight, Blood Pressure, Hypercholesteremia, Diabetes
Interventions: Motivational interviewing to elicit PCO in pediatrics; Behavioral
Lead sponsor: Henry Ford Health System; Other
Eligibility: 2 Years to 18 Years
Enrollment: 703 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Cardiovascular Diseases, Lipid Testing, Primary Prevention of Cardiovascular Disease
Interventions: Mailed patient outreach intervention; Behavioral
Lead sponsor: Northwestern University; Other
Eligibility: 35 Years to 75 Years
Enrollment: 480 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 3
States / cities: Flagstaff, Arizona • Chicago, Illinois

Conditions: Obesity, Cardiovascular Risk Factor, Hyperlipidemia
Interventions: Not listed
Lead sponsor: Susan Smyth; Other
Eligibility: 18 Years to 60 Years
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Cardiovascular Risk Factor, Cardiovascular Diseases, Cardiovascular Stroke, Hypercholesterolemia
Interventions: lerodalcibep, Placebo; Drug · Other
Lead sponsor: LIB Therapeutics LLC; Industry
Eligibility: 18 Years and older
Enrollment: 900 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 3
States / cities: Cincinnati, Ohio

Conditions: Metabolic Syndrome, Inflammation, Hypertriglyceridemia, Obesity
Interventions: Aronia berry juice, Sham comparator; Dietary Supplement · Other
Lead sponsor: Montana State University; Other
Eligibility: 18 Years to 55 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Bozeman, Montana

Conditions: Familial Chylomicronemia, High Risk Severe Hypertriglyceridemia (SHTG)
Interventions: Plozasiran; Drug
Lead sponsor: Arrowhead Pharmaceuticals; Industry
Eligibility: 15 Years and older
U.S. locations: 1
States / cities: Pasadena, California

Conditions: Severe Hypertriglyceridemia
Interventions: Plozasiran Injection, Placebo; Drug
Lead sponsor: Arrowhead Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 446 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 52
States / cities: Garden Grove, California • Lake Forest, California • Montclair, California + 42 more

Conditions: Insulin Resistance, Hypertriglyceridemia
Interventions: Rosiglitazone, Fenofibrate, Weight Loss; Drug · Behavioral
Lead sponsor: Stanford University; Other
Eligibility: 30 Years to 65 Years
Enrollment: 47 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2008
U.S. locations: 1
States / cities: Stanford, California

Conditions: Diabetes Mellitus, Non-Insulin-Dependent, Hypertriglyceridemia
Interventions: Metformin Eicosapentaenoate, Metformin HCl and Vascepa; Drug
Lead sponsor: Thetis Pharmaceuticals LLC; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Baton Rouge, Louisiana

Conditions: Hyperlipidemia
Interventions: Enlicitide, Rosuvastatin, Placebo for Enlicitide, Placebo for Rosuvastatin; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 996 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 35
States / cities: Birmingham, Alabama • Foley, Alabama • Phoenix, Arizona + 30 more

Conditions: Dyslipidemias, High Cholesterol, Hypercholesterolemia, Familial Hypercholesterolemia, Lipid Metabolism Disorder, Metabolic Disease, Lipid Metabolism, Inborn Errors, Genetic Disease, Inborn, Hyperlipoproteinemias
Interventions: Obicetrapib, Placebo; Drug
Lead sponsor: NewAmsterdam Pharma; Industry
Eligibility: 18 Years and older
Enrollment: 354 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 20
States / cities: Jonesboro, Arkansas • Toluca Lake, California • Sarasota, Florida + 17 more

Conditions: Familial Hypercholesterolemia, Cholesterol, Elevated, Genetic Disease
Interventions: Motivational interview (MI); Behavioral
Lead sponsor: Essentia Health; Other
Eligibility: 2 Years to 75 Years
Enrollment: 257 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2025
U.S. locations: 2
States / cities: Duluth, Minnesota

Conditions: Hypertriglyceridemia
Interventions: ARI-3037MO, Placebo; Drug
Lead sponsor: Arisaph Pharmaceuticals Inc; Industry
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 5
States / cities: Tustin, California • Louisville, Kentucky • Auburn, Maine + 2 more

Conditions: Familial Hypercholesterolaemia
Interventions: rosuvastatin calcium; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 315 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Peripheral Arterial Disease
Interventions: Evolocumab 140 mg/mL Subcutaneous Injection 1 milliliter (mL) pre-filled injector Pen x 3 for a monthly dose of 420 mg for 6 months., Placebo 1milliliter (mL) Subcutaneous Injection pre-filled injector Pen x 3 monthly for 6 months.; Drug · Other
Lead sponsor: Leonardo Clavijo; Other
Eligibility: 40 Years to 85 Years
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Lipidemia, Type 2 Diabetes (T2DM), Metabolic Syndrome (MetS)
Interventions: obicetrapib 10 mg + ezetimibe 10 mg FDC daily, Obicetrapib 10 mg, Placebo; Drug · Other
Lead sponsor: NewAmsterdam Pharma; Industry
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 32
States / cities: Sun City West, Arizona • La Jolla, California • Pomona, California + 24 more

Conditions: Hyperlipidemia, Mixed Hyperlipidemia, Dyslipidemia
Interventions: Niacin Extended Release/Lovastatin; Drug
Lead sponsor: In His Image; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 1
States / cities: Tulsa, Oklahoma

Conditions: Obesity, Hyperlipidemia
Interventions: Lifestyle intervention; Behavioral
Lead sponsor: Oregon Health and Science University; Other
Eligibility: Not listed
Enrollment: 3,188 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Lipodystrophy, Diabetes, Hyperlipidemia
Interventions: Metreleptin; Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 6 Months to 98 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2027
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Obesity, Hyperlipidemia, Hypertension, Pre-diabetes, Diabetes
Interventions: Lifestyle Intervention, Print Health Education; Behavioral · Other
Lead sponsor: Northwestern University; Other
Eligibility: 30 Years to 60 Years
Enrollment: 63 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2015
U.S. locations: 2
States / cities: Chicago, Illinois

Conditions: Sickle Cell Disease, Obesity, Childhood, Hypertension, Hyperlipidemia in Children, Hyperglycemia
Interventions: Not listed
Lead sponsor: University of Mississippi Medical Center; Other
Eligibility: 10 Years to 19 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Jackson, Mississippi

Conditions: Obesity, Insulin Resistance, Obesity in Diabetes, Nutritional and Metabolic Diseases, Hyperlipidemia, Hyperglycemia, Cardiovascular Diseases
Interventions: Placebo-Control, Low-Dose Vitamin K2 (menaquinone-7; 45-mcg/d), High-Dose Vitamin K2 (menaquinone-7; 90 mcg/d); Dietary Supplement
Lead sponsor: Augusta University; Other
Eligibility: 8 Years to 17 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Augusta, Georgia

Conditions: Psoriasis, Metabolic Syndrome, Hyperlipidemia, Obesity, Hypertension
Interventions: Etanercept; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2013
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Metabolic Syndrome, PreDiabetes, Hypertension, Obesity, Hyperlipidemias
Interventions: Exercise; Behavioral
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 19 Years to 45 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Aurora, Colorado

Search by objective public record fields.

Pediatric Preventative Health Screenings - Obesity and Family-Centered Outcomes

Promoting Cholesterol Screening

Dietary Sources of Lysophospholipids

Study of Long-Term Efficacy and Safety of LIB003 in CVD or High Risk for CVD Patients Needing Further LDL-C Reduction

Impacts of Aronia on Inflammation and the Gut Microbiome

Treatment Protocol of Plozasiran in Adults With High-Risk Severe Hypertriglyceridemia (SHTG) and in Adults and Adolescents With FCS

Study of Plozasiran (ARO-APOC3) in Adults With Severe Hypertriglyceridemia

Comparing Tricor, Avandia, or Weight Loss to Lower Cardiovascular Risk Factors in People With High Triglycerides.

PK Study Comparing Metformin Eicosapentaenoate to a Combined Dose of Metformin Hydrochloride and Ethyl Ester EPA

A Clinical Study of Enlicitide in Participants With High Cholesterol (MK-0616-037)

Evaluate the Effect of Obicetrapib in Patients With HeFH on Top of Maximum Tolerated Lipid-Modifying Therapies.

Improved Diagnosis of Familial Hypercholesterolemia Across the Northland (ID-FH)

Trial of ARI-3037MO to Reduce Triglyceride Levels in Adults With Severe (≥500 mg/dl) Hypertriglyceridemia

An Study to Evaluate Rosuvastatin in Children and Adolescents With Familial Hypercholesterolaemia

Effect of Evolocumab in Functional Status and LDL Oxidation of Patients With Peripheral Arterial Disease

A Study to Evaluate the Effect of Obicetrapib/Ezetimibe 10 mg Fixed-Dose Combination or Obicetrapib 10 mg Daily on Top of Guideline-Recommended Lipid-Lowering Therapy in Participants With Type 2 Diabetes and/or Metabolic Syndrome

Efficacy Study of Extended-Release Niacin/Lovastatin Versus Usual Care

Body Worlds 3 Nutrition Display

Compassionate Use of Metreleptin in Previously Treated People With Generalized Lipodystrophy

Translating a Heart Disease Lifestyle Intervention Into the Community

Obesity in Pediatric Sickle Cell Disease: A New Phenomenon

Vitamin K to Slow Progression of Dyslipidemia and Diabetes Risk (Vita-K 'n' Kids Study II)

Effects of TNF-alpha Antagonism (Etanercept) in Patients With the Metabolic Syndrome and Psoriasis

Exercise, Sleep Quality and Nocturnal Fat Oxidation in Metabolic Syndrome